Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

H Lundbeck initiates Zicronapine Phase III clinical trial

PBR Staff Writer Published 21 January 2011

H Lundbeck has initiated a Phase III clinical trial to evaluate Zicronapine and expects to recruit around 160 schizophrenia patients.

The study aims to measure the efficacy of Zicronapine and risperidone and their relative impact on key metabolic parameters.

In the trial, the patients will be randomly assigned to Zicronapine (7.5mg/day) or risperidone (5mg/day) treatment in a 1:1 ratio.

Lundbeck Development head and executive vice president Anders Gersel Pedersen said with Zicronapine, they look forward to be able to offer patients and their physicians a new treatment option within an area still characterized by substantial unmet medical needs.

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.